Meinolf Karthaus Selected Research

netupitant

4/2022	Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy.
1/2022	Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
1/2020	Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life.
1/2019	Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
1/2017	NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
1/2015	Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Meinolf Karthaus Research Topics

Disease

31	Neoplasms (Cancer) 01/2024 - 05/2003
26	Colorectal Neoplasms (Colorectal Cancer) 01/2024 - 01/2012
11	Vomiting 07/2023 - 01/2015
11	Nausea 07/2023 - 01/2015
11	Invasive Fungal Infections 07/2020 - 05/2003
10	Aspergillosis 01/2021 - 12/2002
9	Infections 02/2021 - 10/2003
8	Neutropenia 07/2020 - 05/2003
5	Mycoses (Diseases, Fungus) 07/2020 - 05/2003
5	Graft vs Host Disease (Graft-Versus-Host Disease) 09/2014 - 05/2003
5	Candidiasis (Moniliasis) 01/2011 - 10/2003
4	Neoplasm Metastasis (Metastasis) 10/2023 - 01/2008
4	Communicable Diseases (Infectious Diseases) 01/2021 - 10/2003
3	Disease Progression 01/2023 - 01/2019
2	Weight Loss (Weight Reduction) 07/2023 - 05/2004
2	Exanthema (Rash) 01/2022 - 06/2017
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 09/2014 - 01/2009
2	Malnutrition (Nutritional Deficiencies) 02/2010 - 05/2006
2	Malignant Mesothelioma 01/2010 - 07/2008
1	Anticipatory Vomiting 07/2023
1	Second Primary Neoplasms (Neoplasms, Second) 07/2023
1	COVID-19 01/2023
1	Breast Neoplasms (Breast Cancer) 04/2022
1	Esophageal Squamous Cell Carcinoma 01/2022
1	Microsatellite Instability 01/2022
1	Bronchiolitis Obliterans 01/2022
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2022
1	Bacterial Infections (Bacterial Infection) 02/2021
1	Hallucinations (Hallucination) 01/2021
1	Agranulocytosis (Granulocytopenia) 07/2020
1	Mucormycosis 07/2020
1	Paronychia 06/2017

Drug/Important Bio-Agent (IBA)

15	Panitumumab (Vectibix)FDA Link 01/2024 - 01/2012
9	Fluorouracil (Carac)FDA LinkGeneric 04/2024 - 01/2012
9	Leucovorin (Folinic Acid)FDA Link 04/2024 - 01/2012
9	Voriconazole (Vfend)FDA LinkGeneric 01/2021 - 12/2002
8	Palonosetron (Aloxi)FDA Link 04/2022 - 01/2015
7	Amphotericin B (Amphotericin)FDA LinkGeneric 01/2013 - 12/2002
6	netupitantIBA 04/2022 - 01/2015
6	Fluconazole (Zonal)FDA LinkGeneric 09/2014 - 10/2003
5	Biomarkers (Surrogate Marker)IBA 01/2024 - 05/2015
4	Bevacizumab (Avastin)FDA Link 01/2023 - 01/2008
4	Cetuximab (Erbitux)FDA Link 01/2023 - 06/2017
4	posaconazole FDA Link 01/2021 - 01/2009
4	Dexamethasone (Maxidex)FDA LinkGeneric 07/2019 - 01/2015
4	AzolesIBA 02/2017 - 05/2003
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2015 - 05/2003
4	liposomal amphotericin B FDA Link 09/2014 - 01/2009
4	EchinocandinsIBA 01/2013 - 02/2009
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2022 - 01/2015
3	AnthracyclinesIBA 04/2022 - 01/2015
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 07/2014
3	Irinotecan (Camptosar)FDA LinkGeneric 09/2019 - 01/2012
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
2	ErbB Receptors (EGF Receptor)IBA 01/2018 - 07/2014
2	Cisplatin (Platino)FDA LinkGeneric 10/2015 - 07/2008
2	SteroidsIBA 09/2014 - 01/2013
2	Monoclonal AntibodiesIBA 09/2012 - 05/2004
2	LipidsIBA 01/2011 - 02/2009
2	Pemetrexed (MTA)FDA Link 01/2010 - 07/2008
2	Caspofungin (Cancidas)FDA Link 02/2009 - 10/2003
2	Anti-Bacterial Agents (Antibiotics)IBA 04/2008 - 10/2003
2	PolyenesIBA 10/2003 - 05/2003
1	ElectrolytesIBA 07/2023
1	regorafenibIBA 01/2023
1	VaccinesIBA 01/2023
1	Adenosine Triphosphate (ATP)IBA 01/2023
1	Epirubicin (Ellence)FDA LinkGeneric 04/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2022
1	IpilimumabIBA 01/2022
1	avelumabIBA 01/2022
1	NivolumabIBA 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	FluoroquinolonesIBA 02/2021
1	Peptide Hydrolases (Proteases)FDA Link 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	Circulating Tumor DNAIBA 01/2021
1	Alkaline PhosphataseIBA 01/2021
1	Alanine Transaminase (SGPT)IBA 01/2021
1	Antifungal AgentsIBA 07/2020
1	Neurokinin-1 Receptor AntagonistsIBA 07/2019
1	afliberceptIBA 01/2019
1	Thymidine PhosphorylaseIBA 11/2018
1	Trifluridine (Viroptic)FDA LinkGeneric 11/2018
1	NucleosidesIBA 11/2018
1	trifluridine tipiracil drug combinationIBA 11/2018
1	tipiracilIBA 11/2018
1	ThymidineIBA 11/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018
1	MEHD7945AIBA 01/2018

Therapy/Procedure

31	Therapeutics 01/2024 - 05/2003
26	Drug Therapy (Chemotherapy) 07/2023 - 05/2003
4	Central Venous Catheters 01/2021 - 10/2003
3	Stem Cell Transplantation 02/2021 - 09/2014
3	Parenteral Nutrition 01/2021 - 05/2006
2	Catheters 07/2008 - 10/2003
2	Palliative Care (Palliative Therapy) 01/2008 - 05/2004
1	Biological Therapy 01/2018
1	Skin Care 06/2017